Sarepta Will Resume US Elevidys Shipments For Ambulatory DMD Patients

Discussions On Non-Ambulatory Safety Ongoing

 
• By Mandy Jackson
  
The FDA recommended removing a voluntary hold on shipments of Elevidys to ambulatory DMD patients (Shutterstock)

More from Gene Therapies

More from Advanced Therapies